Vision, Integrity, Expertise

Soligenix, Inc. is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec^® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of allogeneic hematopoietic cell transplantation.

orBec^®

orBec^® represents a first-of-its-kind oral, locally acting therapy tailored to treat the GI manifestation of GVHD by reducing the need for systemic immunosuppressive drugs to treat GI GVHD. Click here to learn more about orBec^®.